Table 5.

Cox model measured hazard ratios and 95% confidence interval of coronary artery disease associated with sex, age, and comorbidity restricted on uricosuric agents after propensity-score matching.

Variable	Event	PY	IR	cHR (95%CI)	aHR (95%CI)
MATCHED COHORT
Non-users (n = 2,036)	155	8,882	1.7	1 (ref)	1 (ref)
Users (n = 1,454)	81	6,695	1.2	0.68 (0.52,0.9)**	0.67 (0.51,0.87)**
CUMULATIVE DURATION OF THERAPY (MONTHS)
Non-users	155	8,882	1.7	1 (ref)	1 (ref)
≦1	22	1,708	1.3	0.72 (0.46, 1.12)	0.82 (0.52, 1.29)
1-5	33	2,204	1.5	0.86 (0.59, 1.25)	0.88 (0.6, 1.28)
>5	26	2,784	0.9	0.52 (0.35, 0.8)**	0.44 (0.28, 0.67)***
P for trend				0.003	<0.001
MONTHLY AVERAGE DAILY DOSES OF URATE-LOWERING THERAPY
Non-users	155	8,882	1.7	1 (ref)	1 (ref)
≦0.5	26	2,139	1.2	0.68 (0.45, 1.04)	0.62 (0.41, 0.94)*
0.5–0.8	15	1,524	1.0	0.56 (0.33, 0.95)*	0.55 (0.32, 0.94)*
>0.8	40	3,032	1.3	0.74 (0.52, 1.05)	0.74 (0.52, 1.06)
P for trend				0.02	0.02

IR, incidence rate, per 100 person-years; PY, person-years; CI, confidence interval; cHR, crude hazard ratio; aHR, adjusted hazard ratio, controlling for sex, age, area, every comorbidity, and drug in Table 2;

^*P < 0.05,

^**P < 0.01, and

^***P < 0.001.